

PHARMACY POLICY STATEMENT

Marketplace

BENEFIT TYPE	Pharmacy

Aubagio is a pyrimidine synthesis inhibitor that was approved by the FDA in 2012. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Aubagio has a black box warning for hepatotoxicity and teratogenicity.

Aubagio (teriflunomide) will be considered for coverage when the following criteria are met:

Multiple Sclerosis (MS)

